Prosecution Insights
Last updated: April 19, 2026
Application No. 17/710,076

AGGLOMERATED BOTANICAL MATERIAL FOR ORAL PRODUCTS

Non-Final OA §103
Filed
Mar 31, 2022
Examiner
ALAM, AYAAN A
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
R J Reynolds Tobacco Company
OA Round
5 (Non-Final)
36%
Grant Probability
At Risk
5-6
OA Rounds
3y 5m
To Grant
76%
With Interview

Examiner Intelligence

Grants only 36% of cases
36%
Career Allow Rate
50 granted / 137 resolved
-23.5% vs TC avg
Strong +39% interview lift
Without
With
+39.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
60 currently pending
Career history
197
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
52.0%
+12.0% vs TC avg
§102
11.4%
-28.6% vs TC avg
§112
22.5%
-17.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 137 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims The arguments filed 12/17/2025 are acknowledged and have been fully considered. Claims 1-12, 14, and 17-26 are currently pending. Claim 1 is amended; claims 13 and 15-16 are cancelled; claims 8-12, 14, 17, and 19-26 are withdrawn; no claims are new. Claims 1-7 and 18 are examined on the merits herein. Objections/Rejections Withdrawn Rejections and/or objections not reiterated from previous Office Actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied, and constitute the complete set presently being applied to the instant application. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-7 and 18 are rejected under 35 U.S.C. 103 as being unpatentable over Us Patent 9888712 (Zimmermann, 2018; of record) in view of Okeke (2016), US PGPUB 20220071272 A1 (Castelijn, 2020), and CN 112574475 A (Wang, 2021) and as evidenced by Kramer Industries (“Mesh Size”; of record). Claim 1 is drawn to a method of preparing an agglomerated botanical material having an increased water stability, comprising: combining botanical particle fines (more specifically stems of a plant of the Nicotiana species (Claim 18)) having an average size of about 300 microns or less with a binding agent, the binding agent being an alginate salt combined with hydroxypropyl methyl cellulose; forming agglomerated botanical particles from the combined botanical particle fines and binding agent, the agglomerated botanical particles having an average particle size greater than the botanical particle fines; and treating the agglomerated botanical particles to increase the water stability thereof, wherein the treating step comprises treating the agglomerated botanical particles with a divalent cation solution comprising calcium chloride at a temperature of about 50°C or greater. Zimmermann teaches a method for forming tobacco (i.e., a species of Nicotiana) beads (see Zimmermann, Col. 1 lines 29-32). Zimmermann further teaches “Preferably, the tobacco beads 14 are made of an agglomeration of tobacco fines and water. In one embodiment, the tobacco beads 14 may also include flavorants 16. In a preferred embodiment, the tobacco beads 14 include a binder 18” (see Zimmermann, Col. 4 lines 23-27) and “The tobacco beads 14 can be prepared using known extrusion and spheronization processes for producing pharmaceutical pellets and flavored beads” (see Zimmermann, Col. 4 lines 38-40). Zimmermann defines tobacco fines as “small tobacco particles that are too small for inclusion in tobacco products” (see Zimmermann, Col. 3 lines 64-65) and further teaches “Particles of less than about 60 mesh tend to go airborne during pouching operations, thereby wasting tobacco and creating cleanliness issues during pouching operations. Thus, tobacco particles below 60 mesh are preferably separated out prior to pouching. These particles, which would otherwise be waste, can be formed into tobacco beads using the processes described herein” (see Zimmermann, Col. 4 lines 11-15). As evidenced by Kramer Industries particles smaller than 60 mesh are smaller than 250 micron (see Kramer Industries, Table on pg. 2), and would necessarily have an average size less than 300 microns. The tobacco beads of Zimmermann are “more preferably about 0.3 mm to about 0.7 mm” (see Zimmermann, Col. 4 lines 66-67), and would necessarily have an average size larger than the claimed 300 micron size of the fines. Zimmermann further teaches “The loose, fibrous tobacco material may be provided in any suitable form, including, but not limited to, tobacco lamina, processed tobacco materials such as volume expanded or puffed tobacco, aged tobacco, processed tobacco stems, such as cut-rolled or cut-puffed stems, reconstituted tobacco materials, blends thereof, and the like” (see Zimmermann, Col. 8 lines 39-45, emphasis added). As such, Zimmermann teaches a method of preparing an agglomerated botanical material, comprising combining botanical particle fines comprising stems of a plant of the Nicotiana species (tobacco) having an average size of about 300 microns or less with a binding agent; and forming agglomerated botanical particles from the combined botanical particle fines and binding agent, the agglomerated botanical particles having an average particles size greater than the botanical particle fines. The method of Zimmermann differs from the instantly claimed method in the following ways: Zimmermann does not teach the binder agent being an alginate salt combined with hydroxypropyl methyl cellulose, however Zimmermann teaches that hydroxypropyl methylcellulose (HPMC) is used as a binder in the composition (see Zimmermann, Col. 5, lines 13-33); and Zimmermann does not teach a step of treating with a divalent cation solution comprising calcium chloride. In regards to point 1, Okeke teaches that HPMC and sodium alginate (SA) are known mucoadhesive polymers used with nicotine (see Okeke, abstract; page 32, col. 1, paragraph 2). Okeke also teaches that “[t]he properties of mucoadhesive polymers such as surface charge and solubility play a vital role in their ability to adhere to mucosal surfaces. Charged polymers such as SA demonstrate higher adhesion than non-ionic polymers (e.g. HPMC), because of their ability to form a strong electrostatic interaction with the charged surface of mucin. The use of composite polymeric systems can be adopted to enhance the functional properties of a polymeric dosage form. HPMC is very effective in designing controlled drug delivery systems while SA can be used to enhance the mucoadhesion of a given polymeric dosage form. Further, the anionic nature of SA provides a potential means of interaction of the amine groups of NIC with the carboxylic acid side chains of SA, which could improve mucoadhesion and provide further control of drug release” (see Okeke, page 32, col. 1, paragraph 2). In regards to point 2, Castelijn teaches a method of making a tobacco product (see Castelijn, abstract), such as a pouch comprising a binder such as alginate (see Castelijn, paragraph 0135). The method comprises milling tobacco material and extracting tobacco pulp with a chelating agent, wherein the chelating agent is calcium citrate, calcium diacetate, calcium hexametaphosphate, or monobasic calcium phosphate, among others (see Castelijn, figure 1; paragraphs 0068 and 0085). It is taught that the chelating agent removes transition metals from the tobacco material (see Castelijn, paragraphs 0043 and 0068). It is also taught that the extraction done with water and a chelating agent is done at a temperature of about 75°C to about 100°C (see Castelijn, paragraphs 0068-0070). MPEP 2144.05 states that "[i]n the case where the claimed ranges 'overlap or lie inside ranges disclosed by the prior art' a prima facie case of obviousness exists" quoting In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976). Wang teaches a method of chelating tobacco products with calcium chloride (see Wang, abstract; page 2, contents of the invention, paragraph 4). In regards to claims 1 and 18, it would have been prima facie obvious to a person of ordinary skill in the art, before the effective filing date of the claimed invention, to combine the teachings of Zimmermann with the teachings of Okeke, Castelijn, and Wang to formulate the instant method. Particularly, it would be obvious to one with ordinary skill in the art to use the combination of HPMC with SA as a binder as Okeke teaches that using both together improves mucoadhesion while also providing further control for the release of the drug (see Okeke, page 32, col. 1, paragraph 2). Also, one with ordinary skill in the art would be motivated to add the chelating step of Castelijn to the method of Zimmermann as it would remove transition metals from the tobacco material using one of the chelating agents mentioned, such as calcium chloride as it is known to work as a chelating agent with tobacco products (see Castelijn, paragraphs 0068-0070; Wang, page 2, contents of the invention, paragraph 4). One with ordinary skill in the art would be motivated to combine the method of Zimmermann with the HPMC and SA of Okeke and the chelating step of Castelijn with chelating agent of Wang according to the method of making a tobacco product (see Zimmermann, Col. 4, lines 44-56) to yield predictable results with a reasonable expectation of success. One with ordinary skill in the art would be motivated to combine prior art elements according to known methods to yield predictable results. Further in regards to the use of the chelating agent of Wang, it would be obvious to one with ordinary skill in the art to simply substitute one known chelating agent for another, particularly when both are used for tobacco products, to obtain predictable results with a reasonable expectation of success. One with ordinary skill in the art would be motivated to simply substitute one known element for another to obtain predictable results. Claim 2 is drawn to the method of claim 1, wherein the combining step comprises combing the botanical particle fines with the binding agent at a weight ratio of botanical particle fines to binding agent of from about 0.5:1 to about 5:1. Claim 3 is drawn to the method of claim 1, wherein the combining step comprises combing the botanical particle fines with the binding agent at a weight ratio of botanical particle fines to binding agent of from about 0.8:1 to about 3.25:1. Claim 4 is drawn to the method of claim 1, wherein the combining step comprises combing the botanical particle fines with the binding agent at a weight ratio of botanical particle fines to binding agent of about 3.25 or less. Zimmermann further teaches “For tobacco beads, which include a binder additive, preferably, about 5 wt % to about 90 wt % of the tobacco bead is tobacco particles, and more preferably from about 30 weight % to about 65 weight % of the tobacco bead is tobacco particles” (see Zimmermann, Col. 4 lines 34-37). 30 wt% to 65 wt% of tobacco particles corresponds to a weight ratio of tobacco particles to binding agent of about 0.42:1 to about 1.86:1 as calculated by examiner, overlapping with the instantly claimed ranges of about 0.5:1 to about 5:1, about 0.8:1 to about 3.25:1, and about 3.25 or less. As such, claims 2-4 are rejected as prima facie obvious. Claim 5 is drawn to the method of claim 1, wherein the agglomerated botanical particles have an average particle size greater than about 350 microns. Claim 6 is drawn to the method of claim 1, wherein the agglomerated botanical particles have an average particle size greater than about 400 microns. Claim 7 is drawn to the method of claim 1, wherein the agglomerated botanical particles have an average particle size greater than about 500 microns. Zimmermann teaches “each spheroidal tobacco bead can have a diameter of about 0.1 mm to about 2.5 mm” (see Zimmermann, Col. 4 lines 64-65), corresponding to 100 to 1500 microns. One of ordinary skill in the art would reasonably expect the average tobacco bead to have an average particle size greater than 500 microns. Assuming, arguendo that the tobacco beads of Zimmermann do not have an average size greater than 500 microns, MPEP 2144.04 states “In Gardner v. TEC Syst., Inc., 725 F.2d 1338, 220 USPQ 777 (Fed. Cir. 1984), cert. denied, 469 U.S. 830, 225 USPQ 232 (1984), the Federal Circuit held that, where the only difference between the prior art and the claims was a recitation of relative dimensions of the claimed device and a device having the claimed relative dimensions would not perform differently than the prior art device, the claimed device was not patentably distinct from the prior art device.” In the instant case, one of ordinary skill in the art would expect the 0.1 mm to 2.5 mm tobacco beads to perform the same as the instantly claimed agglomerated particles having an average particle size greater than about 500 microns. As such, claims 5-7 are rejected as prima facie obvious. Response to Arguments Applicant's arguments filed 12/17/2025 have been fully considered but they are not persuasive in view of the modified grounds of rejection as necessitated by amendment. In regards to applicant’s arguments that art does not teach the treatment with a calcium chloride solution, it is pointed out that the rejection of record has been modified as necessitated by amendment to be over Wang as well now. Wang teaches a method of chelating tobacco products with calcium chloride (see Wang, abstract; page 2, contents of the invention, paragraph 4). It would be obvious to one with ordinary skill in the art to simply substitute one known chelating agent for another, particularly when both are used for tobacco products, to obtain predictable results with a reasonable expectation of success. One with ordinary skill in the art would be motivated to simply substitute one known element for another to obtain predictable results. Further, applicant mentions that Castelijn teaches a laundry list of chelating agents, it is pointed out that the list of chelating agents in Wang is much more narrow. The number of species recited is small and thus a person of ordinary skill in the art can immediately envisage the use of calcium chloride as a chelating agent in the instant method. As such, the method of the instant claim is rendered obvious and is not allowed. Conclusion No claims allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to AYAAN A ALAM whose telephone number is (571)270-1213. The examiner can normally be reached M-F 8-5 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bethany Barham can be reached at 571-272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BETHANY P BARHAM/Supervisory Patent Examiner, Art Unit 1611 /A.A.A./ Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Mar 31, 2022
Application Filed
May 09, 2024
Non-Final Rejection — §103
Aug 16, 2024
Response Filed
Oct 31, 2024
Final Rejection — §103
Feb 07, 2025
Request for Continued Examination
Feb 10, 2025
Response after Non-Final Action
May 30, 2025
Non-Final Rejection — §103
Aug 28, 2025
Response Filed
Sep 29, 2025
Final Rejection — §103
Nov 26, 2025
Response after Non-Final Action
Dec 17, 2025
Request for Continued Examination
Dec 18, 2025
Response after Non-Final Action
Jan 08, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599612
PHARMACEUTICAL USE
2y 5m to grant Granted Apr 14, 2026
Patent 12576106
COMPOSITIONS OF NITRATES AND METHODS OF USE THEREOF
2y 5m to grant Granted Mar 17, 2026
Patent 12569588
SELF-ASSEMBLING GRAPHENE OXIDE-PROTEIN MATRIX
2y 5m to grant Granted Mar 10, 2026
Patent 12557816
COMPOSITIONS FOR CONTROLLING A PLANT DISEASE
2y 5m to grant Granted Feb 24, 2026
Patent 12544404
COMPOSITIONS AND METHODS FOR TREATING BONE INJURY
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
36%
Grant Probability
76%
With Interview (+39.2%)
3y 5m
Median Time to Grant
High
PTA Risk
Based on 137 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month